Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer - PubMed
5 days ago
- #immunotherapy
- #clinical trial
- #bladder cancer
- Perioperative enfortumab vedotin plus pembrolizumab and surgery significantly improved event-free and overall survival in muscle-invasive bladder cancer patients ineligible for cisplatin-based chemotherapy.
- At 2 years, event-free survival was 74.7% in the treatment group vs. 39.4% in the control group (hazard ratio 0.40; P<0.001).
- Overall survival at 2 years was 79.7% in the treatment group vs. 63.1% in the control group (hazard ratio 0.50; P<0.001).
- Pathological complete response occurred in 57.1% of the treatment group vs. 8.6% in the control group (P<0.001).
- Adverse events were more common in the treatment group (grade ≥3: 71.3%) compared to the control group (grade ≥3: 45.9%).
- The study was a phase 3, open-label trial with 344 participants randomized into treatment and control groups.